Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Sep;33(9):1511–1515. doi: 10.1128/aac.33.9.1511

Effects of the immunomodulating agent R837 on acute and latent herpes simplex virus type 2 infections.

D I Bernstein 1, C J Harrison 1
PMCID: PMC172692  PMID: 2479335

Abstract

R837 is an immune modulator with no in vitro activity against herpes simplex virus (HSV). We evaluated topical R837 as therapy for genital HSV type 2 infection using the guinea pig model of this disease. Furthermore, we investigated the effect of R837 therapy on acute and latent neural HSV infections. Therapy initiated 12 h after viral inoculation and given twice a day significantly reduced the acute neural infection so that HSV was recovered from only 1 of 64 neural tissue specimens obtained from R837 recipients compared with 43 of 56 specimens obtained from placebo recipients (P less than 0.0001). R837 initiated 36 h after HSV inoculation and given once a day also significantly reduced the total mean lesion score of the acute disease from 14.1 +/- 4.3 to 2.6 +/- 5.3 (P less than 0.0001) and shortened the period of vaginal HSV shedding from 6.9 +/- 1.7 to 3.2 +/- 1.4 days (P less than 0.001). R837-treated animals also developed fewer HSV recurrences than did controls (2.0 +/- 1.7 versus 5.1 +/- 1.7; P less than 0.0002). Latent HSV was detected in 23 of 24 dorsal root ganglia explant cultures from placebo recipients but in only 2 of 30 cultures from R837-treated animals, and HSV in these 2 cultures was detectable only with the addition of a demethylating agent. Topical R837 exhibited in vivo anti-HSV activity, reducing both acute and latent neural infections as well as acute and recurrent genital disease.

Full text

PDF
1511

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aurelian L., Rinehart C. L., Wachsman M., Kulka M., Ts'o P. O. Augmentation of natural immune defence mechanisms and therapeutic potential of a mismatched double-stranded polynucleotide in cutaneous herpes simplex virus type 2 infection. J Gen Virol. 1987 Nov;68(Pt 11):2831–2838. doi: 10.1099/0022-1317-68-11-2831. [DOI] [PubMed] [Google Scholar]
  2. Bernstein D. I., Kappes J. C. Enhanced in vitro reactivation of latent herpes simplex virus from neural and peripheral tissues with hexamethylenebisacetamide. Arch Virol. 1988;99(1-2):57–65. doi: 10.1007/BF01311023. [DOI] [PubMed] [Google Scholar]
  3. Bernstein D. I., Stanberry L. R., Harrison C. J., Kappes J. C., Myers M. G. Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. J Gen Virol. 1986 Aug;67(Pt 8):1601–1612. doi: 10.1099/0022-1317-67-8-1601. [DOI] [PubMed] [Google Scholar]
  4. Bernstein D. I., Stanberry L. R., Harrison C. J., Shukla R., Kappes J. C., Myers M. G. Antibody response to herpes simplex virus glycoprotein D: effects of acyclovir and relation to recurrence. J Infect Dis. 1987 Sep;156(3):423–429. doi: 10.1093/infdis/156.3.423. [DOI] [PubMed] [Google Scholar]
  5. Bernstein D. I., Stanberry L. R. Zosteriform spread of herpes simplex virus type 2 genital infection in the guinea-pig. J Gen Virol. 1986 Sep;67(Pt 9):1851–1857. doi: 10.1099/0022-1317-67-9-1851. [DOI] [PubMed] [Google Scholar]
  6. Bryson Y. J., Dillon M., Lovett M., Acuna G., Taylor S., Cherry J. D., Johnson B. L., Wiesmeier E., Growdon W., Creagh-Kirk T. Treatment of first episodes of genital herpes simplex virus infection with oral acyclovir. A randomized double-blind controlled trial in normal subjects. N Engl J Med. 1983 Apr 21;308(16):916–921. doi: 10.1056/NEJM198304213081602. [DOI] [PubMed] [Google Scholar]
  7. Bryson Y., Dillon M., Lovett M., Bernstein D., Garratty E., Sayre J. Treatment of first episode genital HSV with oral acyclovir: long term follow-up of recurrences. A preliminary report. Scand J Infect Dis Suppl. 1985;47:70–75. [PubMed] [Google Scholar]
  8. Chen M., Griffith B. P., Lucia H. L., Hsiung G. D. Efficacy of S26308 against guinea pig cytomegalovirus infection. Antimicrob Agents Chemother. 1988 May;32(5):678–683. doi: 10.1128/aac.32.5.678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Corey L., Mindel A., Fife K. H., Sutherland S., Benedetti J., Adler M. W. Risk of recurrence after treatment of first-episode genital herpes with intravenous acyclovir. Sex Transm Dis. 1985 Oct-Dec;12(4):215–218. doi: 10.1097/00007435-198510000-00009. [DOI] [PubMed] [Google Scholar]
  10. Dietrich F. M., Hochkeppel H. K., Lukas B. Enhancement of host resistance against virus infections by MTP-PE, a synthetic lipophilic muramyl peptide--I. Increased survival in mice and guinea pigs after single drug administration prior to infection, and the effect of MTP-PE on interferon levels in sera and lungs. Int J Immunopharmacol. 1986;8(8):931–942. doi: 10.1016/0192-0561(86)90095-0. [DOI] [PubMed] [Google Scholar]
  11. Eron L. J., Harvey L., Toy C., Santomauro D. Interferon in the prevention of genital herpes recurrence. Antimicrob Agents Chemother. 1986 Oct;30(4):608–610. doi: 10.1128/aac.30.4.608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Eron L. J., Toy C., Salsitz B., Scheer R. R., Wood D. L., Nadler P. I. Therapy of genital herpes with topically applied interferon. Antimicrob Agents Chemother. 1987 Jul;31(7):1137–1139. doi: 10.1128/aac.31.7.1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Field H. J., Bell S. E., Elion G. B., Nash A. A., Wildy P. Effect of acycloguanosine treatment of acute and latent herpes simplex infections in mice. Antimicrob Agents Chemother. 1979 Apr;15(4):554–561. doi: 10.1128/aac.15.4.554. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Fraser-Smith E. B., Smee D. F., Matthews T. R. Efficacy of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine against primary and recrudescent genital herpes simplex virus type 2 infections in guinea pigs. Antimicrob Agents Chemother. 1983 Dec;24(6):883–887. doi: 10.1128/aac.24.6.883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Freeman D. J., McKeough M. B., Spruance S. L. Recombinant human interferon-alpha A treatment of an experimental cutaneous herpes simplex virus type 1 infection of guinea pigs. J Interferon Res. 1987 Apr;7(2):213–222. doi: 10.1089/jir.1987.7.213. [DOI] [PubMed] [Google Scholar]
  16. Harrison C. J., Jenski L., Voychehovski T., Bernstein D. I. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antiviral Res. 1988 Dec 1;10(4-5):209–223. doi: 10.1016/0166-3542(88)90032-0. [DOI] [PubMed] [Google Scholar]
  17. Klein R. J., Friedman-Kien A. E., DeStefano E. Latent herpes simplex virus infections in sensory ganglia of hairless mice prevented by acycloguanosine. Antimicrob Agents Chemother. 1979 May;15(5):723–729. doi: 10.1128/aac.15.5.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kuhls T. L., Sacher J., Pineda E., Santomauro D., Wiesmeier E., Growdon W. A., Bryson Y. J. Suppression of recurrent genital herpes simplex virus infection with recombinant alpha 2 interferon. J Infect Dis. 1986 Sep;154(3):437–442. doi: 10.1093/infdis/154.3.437. [DOI] [PubMed] [Google Scholar]
  19. Mertz G. J., Critchlow C. W., Benedetti J., Reichman R. C., Dolin R., Connor J., Redfield D. C., Savoia M. C., Richman D. D., Tyrrell D. L. Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA. 1984 Sep 7;252(9):1147–1151. [PubMed] [Google Scholar]
  20. Mindel A., Kinghorn G., Allason-Jones E., Woolley P., Barton I., Faherty A., Jeavons M., Williams P., Patou G. Treatment of first-attack genital herpes--acyclovir versus inosine pranobex. Lancet. 1987 May 23;1(8543):1171–1173. doi: 10.1016/s0140-6736(87)92144-1. [DOI] [PubMed] [Google Scholar]
  21. Park N. H., Pavan-Langston D., Hettinger M. E., McLean S. L., Albert D. M., Lin T. S., Prusoff W. H. Topical therapeutic efficacy of 9-(2-hydroxyethoxymethyl)guanine and 5-iodo-5'-amino-2',5'-dideoxyuridine on oral infection with herpes simplex virus in mice. J Infect Dis. 1980 May;141(5):575–579. doi: 10.1093/infdis/141.5.575. [DOI] [PubMed] [Google Scholar]
  22. Scriba M. Herpes simplex virus infection in guinea pigs: an animal model for studying latent and recurrent herpes simplex virus infection. Infect Immun. 1975 Jul;12(1):162–165. doi: 10.1128/iai.12.1.162-165.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Stanberry L. R., Bernstein D. I., Kit S., Myers M. G. Genital reinfection after recovery from initial genital infection with herpes simplex virus type 2 in guinea pigs. J Infect Dis. 1986 Jun;153(6):1055–1061. doi: 10.1093/infdis/153.6.1055. [DOI] [PubMed] [Google Scholar]
  24. Stanberry L. R., Kern E. R., Richards J. T., Abbott T. M., Overall J. C., Jr Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J Infect Dis. 1982 Sep;146(3):397–404. doi: 10.1093/infdis/146.3.397. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES